Dasatinib structure and trade name

Dasatinib (Dasatinib) is a small molecule tyrosine kinase inhibitor mainly used to treat certain types of leukemia, such as chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Its chemical structure is characterized by its bicyclic structure containing a phenyl and a thiazole ring, which gives it a unique advantage in targeting kinase mechanisms. During the use of dasatinib, doctors usually choose the most suitable treatment plan based on the patient's genetic mutation status.

The chemical formula of dasatinib isC22H26N6O2S, and its molecular weight is approximately 398.56g/mol. There are multiple functional groups in its structure, including sulfur, nitrogen and oxygen atoms. These structural features give it good drug activity and selectivity. Dasatinib binds to BCR-ABL tyrosine kinase and blocks its activity, thereby inhibiting the proliferation of cancer cells. The drug also has certain inhibitory effects on a variety of other kinases, including SRC family kinases, making it potentially useful in the treatment of various tumors.

In terms of trade name, the main brand name of dasatinib isSprycel, produced by Pfizer. Since its launch, Sprycel has become one of the important drugs for the treatment of chronic myelogenous leukemia and acute lymphoblastic leukemia. According to clinical trial results, Sprycel has shown excellent efficacy and tolerability in the treatment of these diseases, and is often used by doctors as a first-line treatment option.

Dasatinib is usually administered orally, and the recommended dose will be adjusted based on the patient's specific condition. Patients need to regularly monitor blood indicators while taking dasatinib to evaluate the drug's efficacy and possible side effects. Some common side effects include fatigue, gastrointestinal discomfort, rash, etc. Although most patients can tolerate it, when severe side effects occur, the treatment plan needs to be adjusted in time.